Artelo Biosciences, Inc
Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system (ECS). Its pipeline is built around licensed and internally developed product candidates rather than marketed drugs, so the company is still in the research, preclinical, and clinical development phase. The company’s disclosed programs include ART12.11, a solid-state CBD composition co-formed with TMP being developed for anxiety disorders and rare/orphan diseases, and ART27.13, which is being advanced with third-party manufacturing support. Artelo’s strategy is to target validated biological pathways where it believes differentiated cannabinoid-derived or lipid-signaling therapies can address unmet medical needs. Because it has not yet generated product revenue, the business remains dependent on financing, licensing, and successful clinical execution.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueDrug candidates under preclinical or clinical development, including ART12.11 and ART27.13.
In-licensed pharmaceutical and biotechnology IP used to build the pipeline.
Discovery, preclinical studies, clinical trials, and regulatory preparation for future products.
Customers
Artelo does not currently sell commercial products, so its direct customers are not end-market patients today. In the future, if approved, its therapies would be prescribed by physicians and dispensed through regulated healthcare channels for conditions such as anxiety, pain, inflammation, neurological disease, epilepsy, dermatologic conditions, and rare/orphan diseases. The company also relies on licensors, contract manufacturers, clinical trial vendors, and research partners as critical counterparties in its development model. Commercial success would depend on physicians, payers, and healthcare systems accepting the clinical value and reimbursement profile of any approved product. For now, the company’s 'customers' are effectively the scientific, regulatory, and partnering stakeholders needed to advance its pipeline.
Patients who may receive approved Artelo therapies for anxiety, rare/orphan diseases, pain, inflammation, neurological disease, epilepsy, or dermatologic conditions.
Prescribers who would adopt the company’s therapies if clinical data support efficacy, safety, and differentiation.
Insurers and health systems that would influence market access and uptake through coverage decisions.
CROs, trial sites, and investigators that execute studies and generate the data needed for approvals.
Third parties that provide IP, manufacturing, and commercialization support to advance product candidates.
Strategy
Artelo’s strategy is to build a pipeline around lipid-signaling modulation, including the endocannabinoid system, and to focus on therapeutic areas with validated biology and unmet medical need. The company is prioritizing ART12.11 for anxiety disorders and rare/orphan diseases based on preclinical results and a commercial precedent for CBD-containing products in a rare-disease setting. It also intends to continue licensing intellectual property from pharmaceutical and biotechnology companies and research institutions to expand its pipeline. Because it has no internal sales and marketing organization, the company may partner for commercialization or build those capabilities later if development succeeds. The strategy is therefore centered on scientific differentiation, IP access, and capital-efficient development until a product candidate is approvable.
The program is a key differentiated asset and the company’s disclosed anxiety and rare-disease strategy centers on it.
Artelo relies on in-licensed IP to build a broader portfolio without having to originate every asset internally.
The company lacks internal sales, marketing, and distribution capabilities and may need partners to reach market.
As a clinical-stage company with no revenue, financing discipline is essential to keep programs moving.
Geography
Artelo is headquartered in Solana Beach, California and is based in the United States, but its business model is not tied to a large commercial footprint yet because it has no product revenue. The company disclosed that it is conducting clinical trials in the UK, which also makes it eligible for UK R&D tax credits subject to changing rules. Management also refers to the possibility of commercialization in the United States or overseas, indicating that future market access could be international. Geography matters mainly through clinical trial execution, regulatory approvals, manufacturing supply chains, and tax-credit eligibility rather than through current sales concentration. As the pipeline advances, the company’s exposure to U.S. and foreign regulatory regimes will become more important.
Risks
Artelo is exposed to the classic risks of a clinical-stage biotech company: it has no product revenue, limited operating history, and a high dependence on external financing to fund development. Its pipeline depends on successful clinical execution, regulatory approvals, and the ability to maintain rights under third-party licenses, any of which could delay or terminate programs. The company also depends on contract manufacturers and third-party service providers, so supply-chain or quality failures could disrupt trials. More broadly, cannabinoid-derived and ECS-based therapies face scientific, regulatory, reimbursement, and competitive risks because the market includes large pharmaceutical companies, biotech peers, and alternative treatments. UK R&D tax credit rules, changing health-care regulation, and market acceptance of any approved product are additional business-specific uncertainties.
- Additional financing riskImpact: CriticalLikelihood: High
The company has no product revenue and must fund research, trials, and operations through external capital.
Exposure: Corporate runway and program continuity
- Clinical development and regulatory delayImpact: HighLikelihood: High
Trial timing and approval outcomes are uncertain and can be affected by protocol, safety, or regulatory issues.
Exposure - License compliance and IP lossImpact: HighLikelihood: Medium
The business depends on third-party patent licenses that are vital to its development programs.
Exposure: Licensed product candidates and pipeline rights
- Manufacturing and supply-chain dependenceImpact: HighLikelihood: Medium
A third-party CMO supplies materials for clinical trials, creating execution and quality risk.
Exposure: Clinical trial supply for ART27.13
- UK R&D tax credit policy changesImpact: MediumLikelihood: High
The company currently benefits from UK R&D tax credits tied to clinical trial activity.
Exposure: Non-dilutive funding and cash burn
- Competitive market for cannabinoid-derived therapiesImpact: MediumLikelihood: Medium
The company competes against approved therapies, emerging biotech programs, and academic research.
Exposure
Accounting
Judgemental itemsCosts are expensed as incurred, so the timing of studies and development work directly affects reported losses.
Impact: Quarterly operating loss and comparability
Equity awards are used to attract and retain personnel and can be material relative to total expenses.
Impact: General and administrative expense and dilution analysis
Changes in fair value flow through other income and can create volatility unrelated to core operations.
Impact: Net loss and non-operating income
Tax credits tied to clinical activity can offset expense, but eligibility rules may change.
Impact: Cash flow and effective development cost
Financing instruments affect liquidity, interest expense, and potential dilution.
Impact: Capital structure and per-share metrics
Similar listed companies
Publicly listed companies with a comparable business focus.
Filana Therapeutics, Inc
FLNA · Pharmaceutical Preparations
Forte Biosciences, Inc.
Pharmaceutical Preparations
CNBX Pharmaceuticals Inc.
CNBX · Pharmaceutical Preparations
Anebulo Pharmaceuticals, Inc.
ANEB · Pharmaceutical Preparations
Satellos Bioscience Inc.
MSLE · Pharmaceutical Preparations
LeonaBio, Inc.
LONA · Biological Products, (No Diagnostic Substances)
Last updated: 24/09/2026